Neuritogenic and survival-promoting effects of the P2 peptide derived from a homophilic binding site in the neural cell adhesion molecule.
The neural cell adhesion molecule (NCAM) plays a pivotal role in neural development, regeneration, and plasticity. NCAM mediates adhesion and subsequent signal transduction through NCAM-NCAM binding. Recently, a peptide ligand termed P2 corresponding to a 12-amino-acid sequence in the FG loop of the second Ig domain of NCAM was shown to mimic NCAM homophilic binding as reflected by induction of neurite outgrowth in hippocampal neurons. We demonstrate here that in concentrations between 0.1 and 10 microM, P2 also induced neuritogenesis in primary dopaminergic and cerebellar neurons. Furthermore, it enhanced the survival rate of cerebellar neurons although not of mesencephalic dopaminergic neurons. Moreover, our data indicate that the protective effect of P2 in cerebellar neurons was due to an inhibition of the apoptotic process, in that caspase-3 activity and the level of DNA fragmentation were lowered by P2. Finally, treatment of neurons with P2 resulted in phosphorylation of the ser/thr kinase Akt. Thus, a small peptide mimicking homophilic NCAM interaction is capable of inducing differentiation as reflected by neurite outgrowth in several neuronal cell types and inhibiting apoptosis in cerebellar granule neurons.
Pedersen
Martin V
MV
The Protein Laboratory, Institute of Molecular Pathology, University of Copenhagen, Panum Institute 6.2, Copenhagen, Denmark.
Køhler
Lene B
LB
Ditlevsen
Dorte K
DK
Li
Shizhong
S
Li
Shizong
S
Berezin
Vladimir
V
Bock
Elisabeth
E
D000818:Animals; D000831:Animals, Newborn; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002531:Cerebellum / Q000166:cytology / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian; D005260:Female; D019922:GAP-43 Protein / Q000378:metabolism; D051100:Glial Cell Line-Derived Neurotrophic Factor; D020287:In Situ Nick-End Labeling; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000196:embryology / Q000254:growth & development; D009185:Myelin Proteins / Q000494:pharmacology*; D009414:Nerve Growth Factors / Q000494:pharmacology; D019006:Neural Cell Adhesion Molecules / Q000378:metabolism*; D016501:Neurites / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D016627:Oxidopamine / Q000494:pharmacology; D011247:Pregnancy; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D051381:Rats; D017208:Rats, Wistar; D013565:Sympatholytics / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
D019922:GAP-43 Protein; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009185:Myelin Proteins; D009414:Nerve Growth Factors; D019006:Neural Cell Adhesion Molecules; C425263:P2 peptide; D011518:Proto-Oncogene Proteins; D013565:Sympatholytics; D007334:Insulin-Like Growth Factor I; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; C494920:Akt1 protein, rat; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases